Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thymoquinone-oxime
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Thymoquinone-oxime (TQ-Ox) is a novel synthetic oxime derivative of thymoquinone, the primary bioactive constituent of *Nigella sativa* (black cumin). Developed as a potential antineoplastic agent, TQ-Ox has demonstrated significant cytotoxic, genotoxic, and pro-apoptotic activities in preclinical models of ovarian cancer. Its mechanism of action involves the induction of intracellular reactive oxygen species (iROS) and calcium (iCa2+) accumulation, leading to the depletion of glutathione (GSH) levels and the loss of mitochondrial membrane potential (MMP). These cellular changes culminate in DNA damage and the activation of apoptotic pathways, making it a candidate for further investigation in gynecological malignancies.
02
Targets
DNAGSH (Glutathione)
Beyond the preview
Go deeper on thymoquinone-oxime.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thymoquinone-oxime.